Citigroup Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its target price cut by Citigroup from $10.00 to $7.00 in a research report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts also recently commented on the company. Barclays decreased their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. UBS Group dropped their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research report on Friday, August 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, GoodRx presently has an average rating of “Moderate Buy” and an average target price of $8.86.

GoodRx Stock Performance

Shares of GDRX stock opened at $4.15 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The business has a fifty day moving average of $6.55 and a 200 day moving average of $7.42. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -138.33, a price-to-earnings-growth ratio of 3.22 and a beta of 1.39. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GoodRx

Several hedge funds and other institutional investors have recently made changes to their positions in GDRX. Rubric Capital Management LP raised its stake in GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after purchasing an additional 943,226 shares during the last quarter. Millennium Management LLC raised its position in shares of GoodRx by 36.5% in the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after buying an additional 1,102,758 shares during the last quarter. American Century Companies Inc. purchased a new position in shares of GoodRx in the second quarter worth about $18,183,000. Point72 Asset Management L.P. acquired a new position in GoodRx during the third quarter worth about $11,295,000. Finally, Geode Capital Management LLC grew its stake in GoodRx by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock valued at $6,823,000 after acquiring an additional 58,610 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.